FDA identifies recall of Emergent's decontamination kits as most serious




  • In US
  • 2023-01-26 15:28:58Z
  • By Reuters
 

(Reuters) - The U.S. Food and Drug Administration on Thursday classified the recall of Emergent BioSolutions Inc's skin decontamination lotion kits as the most serious type.

The contract manufacturer began the recall of 3500 units of the kit in November, after receiving three customer complaints of leakage from the packets.

The kits are carried by members of the military and are intended to remove chemical warfare agents and harmful T-2 toxin from the skin.

Emergent said that so far no serious injuries or deaths related to the issue were reported.

FDA says the leakage could cause loss or drying out of the lotion content, reducing the effectiveness of the kit and prolonged exposure to the leaked lotion.

Damaged lotion content could also make an individual, already exposed to chemical warfare, more vulnerable to health hazards.

Emergent did not immediately respond to a Reuters request for comment.

(Reporting by Aditya Samal; Editing by Anil D'Silva)

COMMENTS

More Related News

Eye ointment recalled after earlier EzriCare eyedrops recall linked to infection outbreak, death
Eye ointment recalled after earlier EzriCare eyedrops recall linked to infection outbreak, death

Weeks after EzriCare eyedrops were recalled after being linked to several infections and a death, the parent company is recalling its eye ointment.

US FDA panel votes against effectiveness of Biogen
US FDA panel votes against effectiveness of Biogen's ALS drug
  • US
  • 2023-03-22 21:16:15Z

The FDA panel voted 5 to 3 against the drug, tofersen, as an effective treatment for ALS patients with mutations in a specific gene that leads to...

FDA Lacks the Tools to Prevent Surprise Drug Shortages, Senators Say
FDA Lacks the Tools to Prevent Surprise Drug Shortages, Senators Say
  • World
  • 2023-03-22 19:29:41Z

(Bloomberg) -- US regulators, coping with more than 100 drug shortages, don't have enough information to predict which medications will run low next...

US FDA expands use of Regeneron
US FDA expands use of Regeneron's cholesterol drug in young children
  • US
  • 2023-03-22 11:35:11Z

The drug, Evkeeza, was approved in February 2021 as an additional treatment with other lipid-lowering therapies, for patients aged 12 years and above with...

Lab-grown chicken clears FDA safety hurdle
Lab-grown chicken clears FDA safety hurdle

GOOD Meat still needs approval from the Agriculture Department before it can sell the product line in the U.S.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US